share_log

Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients

Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients

Pliant Therapeutics的藥物試驗顯示有望逆轉患者的肺纖維化
Benzinga ·  05/14 10:39

On Tuesday, Pliant Therapeutics Inc (NASDAQ:PLRX) announced topline data from a Phase 2a PET Imaging trial of bexotegrast (PLN-74809) evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF) characterized by excessive collagen deposition in the lung.

週二,Pliant Therapeutics Inc(納斯達克股票代碼:PLRX)公佈了bexotegrast(PLN-74809)2a期PET成像試驗的主要數據,該試驗評估了以肺部膠原蛋白沉積過多爲特徵的特發性肺纖維化(IPF)患者肺部膠原蛋白總水平的變化。

Bexotegrast-treated patients showed reduced total lung collagen post-treatment as measured by positron emission tomography (PET) imaging, compared to increased total lung collagen in the placebo group, suggesting potential reversal of fibrosis.

與安慰劑組的肺膠原蛋白總量增加相比,通過正電子發射斷層掃描(PET)成像測量,接受Bexotegrast治療的患者在治療後肺部膠原蛋白總量減少,這表明纖維化可能逆轉。

After 12 weeks of treatment, bexotegrast-treated patients showed a reduction in standardized uptake value (SUV) of 68GA-CBP8 in the lung compared to an increase in placebo.

經過12周的治療,與安慰劑的增加相比,接受bexotegrast治療的患者肺中 68GA-CBP8 的標準攝取值(SUV)有所降低。

68GA-CBP8 is a PET ligand that binds to type 1 collagen.

68GA-CBP8 是一種與 1 型膠原蛋白結合的 PET 配體。

This reduction in SUV indicates reduced total lung collagen in the treated group, suggesting a potential reversal of fibrosis.

SUV的減少表明接受治療組的肺部膠原蛋白總量減少,這表明纖維化有可能逆轉。

Bexotegrast-treated patients demonstrated improvements in forced vital capacity (FVC) and reduced cough severity compared to placebo.

與安慰劑相比,接受Bexotegrast治療的患者表現出強迫肺活量(FVC)的改善和咳嗽的嚴重程度降低。

The trial's exploratory efficacy endpoints assessed changes in FVC forced vital capacity percent predicted (FVCpp), patient-reported cough severity, and fibrosis biomarkers.

該試驗的探索性療效終點評估了FVC強制肺活量預測百分比(fvCPP)、患者報告的咳嗽嚴重程度和纖維化生物標誌物的變化。

Bexotegrast-treated patients experienced improved lung function, as measured by FVC and FVCpp, with a clear separation from placebo.

根據FVC和fvCPP的測量,接受Bexotegrast治療的患者的肺功能得到改善,與安慰劑明顯分開。

Across all time points, bexotegrast-treated patients experienced reduced patient-reported cough severity compared to placebo patients.

在所有時間點上,與安慰劑患者相比,接受bexotegrast治療的患者報告的咳嗽嚴重程度有所降低。

At weeks 4 and 12, bexotegrast-treated patients demonstrated a reduction in circulating biomarkers integrin beta-6 and PRO-C3 relative to placebo.

在第 4 周和第 12 周,與安慰劑相比,經過 bexotegrat 治療的患者表現出循環生物標誌物整合素 β-6 和 PRO-C3 的含量有所減少。

PRO-C3, a serum biomarker of type III collagen synthesis, is elevated in patients with IPF and associated with progressive disease.

PRO-C3 是 III 型膠原蛋白合成的血清生物標誌物,在 IPF 患者中升高,與進行性疾病有關。

Bexotegrast was well tolerated at 160 mg over 12 weeks of treatment, with no serious adverse events reported.

在12周的治療中,160毫克的Bexotegrast耐受性良好,沒有報告嚴重的不良事件。

Most frequently reported treatment-emergent adverse events were mild in severity with no trial discontinuations.

最常報告的治療緊急不良事件的嚴重程度較輕,沒有中止試驗。

Price Action: PLRX shares are up 1.3% at $13.90 at last check Tuesday.

價格走勢:週二最後一次檢查時,PLRX股價上漲1.3%,至13.90美元。

Photo: Shutterstock

照片:Shutterstock

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論